Your browser doesn't support javascript.
loading
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
Janes, Holly; Fisher, Leigh H; Kee, Jia Jin; Parameswaran, Lalitha; Goepfert, Paul A; Falsey, Ann R; Ludwig, James; Magaret, Craig A; Gilbert, Peter B; Kublin, James G; Rouphael, Nadine; Sobieszczyk, Magdalena E; El Sahly, Hana M; Baden, Lindsey R; Grinsztejn, Beatriz; Walsh, Stephen R; Gray, Glenda E; Kotloff, Karen L; Gay, Cynthia L; Greninger, Alexander L; Tapia, Milagritos D; Hammershaimb, E Adrianne; Priddy, Frances H; Green, Justin A; Struyf, Frank; Dunkle, Lisa; Neuzil, Kathleen M; Corey, Lawrence; Huang, Yunda.
Afiliación
  • Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Fisher LH; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Parameswaran L; New York University Langone Vaccine Center, New York University Grossman School of Medicine, New York, New York, USA.
  • Goepfert PA; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Falsey AR; Infectious Disease Division, University of Rochester, Rochester, New York, USA.
  • Ludwig J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Magaret CA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Rouphael N; Hope Clinic, Emory University, Atlanta, Georgia, USA.
  • Sobieszczyk ME; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
  • Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Grinsztejn B; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
  • Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Gray GE; South African Medical Research Council, Cape Town, South Africa.
  • Kotloff KL; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Gay CL; Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Greninger AL; Department of Medicine, Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA.
  • Tapia MD; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Hammershaimb EA; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Priddy FH; Moderna, Inc, Cambridge, Massachusetts, USA.
  • Green JA; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom.
  • Struyf F; Janssen Research and Development, Beerse, Belgium.
  • Dunkle L; Novavax, Inc, Gaithersburg, Maryland, USA.
  • Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
J Infect Dis ; 2024 Sep 03.
Article en En | MEDLINE | ID: mdl-39225478
ABSTRACT
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos